knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 23:00:10 - browse：49

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Shingles, which affected Dianne Feinstein, is on the rise

WSS

Mindstrong's demise and the future of mental health care

Why depression after traumatic brain injury is distinct

Biogen shutters digital health group, ends Apple study, in cost cutting move

EPA limits use of carcinogenic gas for sterilizing medical devices

Steward Health Care Massachusetts hospitals face fiscal disaster

Inequities make cancer less preventable for women: report

explore

knowledge

entertainment

Apple is now the first public company to be valued at $3 trillion

Boston's new lab space is opening empty

The high cost of giving birth even with insurance

Would Medicare drug price negotiations stall in a shutdown?

As demand for Covid shots wanes, Moderna seeks its next success

After a drawn out lobbying fight, ARPA

Hepatitis C has a cure — but many Americans still lack access to it

Why depression after traumatic brain injury is distinct

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: CAR

focus

How one patient went off dialysis — and others can too

Kaiser Permanente unions announce official strike date

Paxlovid should be available without a positive Covid test

WuXi out of biotech trade group, U.S. and China relations to blame

Amid AI frenzy, a top HHS official's quest to create safeguards

How one patient went off dialysis — and others can too

explore

Wikipedia

focus

focus